Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
Ashu Rastogi, Anil Bhansali
Diabetes Therapy (2017) Vol. 8, Iss. 6, pp. 1245-1251
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets
Nikoletta Pechlivani, Ramzi Ajjan
Frontiers in Cardiovascular Medicine (2018) Vol. 5
Open Access | Times Cited: 177
Sodium–glucose cotransporter inhibitors and oxidative stress: An update
Habib Yaribeygi, Stephen L. Atkin, Alexandra E. Butler, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 4, pp. 3231-3237
Closed Access | Times Cited: 129
Metabolic Targets in Nonalcoholic Fatty Liver Disease
William P. Esler, Kendra K. Bence
Cellular and Molecular Gastroenterology and Hepatology (2019) Vol. 8, Iss. 2, pp. 247-267
Open Access | Times Cited: 122
Evolving spectrum of diabetic nephropathy
Jonathan Kopel, Camilo Pena-Hernandez, Kenneth Nugent
World Journal of Diabetes (2019) Vol. 10, Iss. 5, pp. 269-279
Open Access | Times Cited: 90
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 81
Management of oxidative stress and inflammation in cardiovascular diseases: mechanisms and challenges
Thoria Donia, Abeer A. Khamis
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 26, pp. 34121-34153
Closed Access | Times Cited: 63
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Jaime A. Davidson
Postgraduate Medicine (2019) Vol. 131, Iss. 4, pp. 251-260
Open Access | Times Cited: 64
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2019) Vol. 11, Iss. 2, pp. 369-386
Open Access | Times Cited: 59
Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease
Laetitia Dou, Noémie Jourde‐Chiche
Toxins (2019) Vol. 11, Iss. 10, pp. 578-578
Open Access | Times Cited: 49
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Amar Ali, Steve Baín, Debbie Hicks, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1595-1622
Open Access | Times Cited: 45
Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study
Uttam A Thakur, Anil Bhansali, Rajesh Gupta, et al.
Obesity Surgery (2020) Vol. 31, Iss. 1, pp. 84-92
Closed Access | Times Cited: 42
Tripterygium and its extracts for diabetic nephropathy: Efficacy and pharmacological mechanisms
Weijun Huang, Weijing Liu, Yonghua Xiao, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 121, pp. 109599-109599
Open Access | Times Cited: 40
SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports
Hibathulla Palapra, Subeesh K. Viswam, Vivekanandan Kalaiselvan, et al.
International Journal of Clinical Pharmacy (2022) Vol. 44, Iss. 6, pp. 1425-1433
Closed Access | Times Cited: 19
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
Andreas P. Katsenos, Athena S. Davri, Yannis V. Simos, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 1, pp. 105-123
Closed Access | Times Cited: 27
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, et al.
Diabetes Care (2018) Vol. 42, Iss. 2, pp. 318-326
Open Access | Times Cited: 32
Transcultural Diabetes Care in The United States – A Position Statement by the American Association of Clinical Endocrinologists
Jeffrey I. Mechanick, Stephanie Adams, Jaime A. Davidson, et al.
Endocrine Practice (2019) Vol. 25, Iss. 7, pp. 729-765
Open Access | Times Cited: 28
Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis
Naveen Hegde, Ankit Kumar, Amol Patil, et al.
Acta Diabetologica (2023) Vol. 60, Iss. 10, pp. 1311-1331
Closed Access | Times Cited: 6
Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
Ji‐Yu Wang, Yanzhen Cheng, Shuangli Yang, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 16
Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.
Fayez El Shear
PubMed (2019) Vol. 9, Iss. 5, pp. 91-108
Closed Access | Times Cited: 15
Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus
Iouri Banakh, Ross Kung, Sachin Gupta, et al.
Clinical Case Reports (2019) Vol. 7, Iss. 5, pp. 1087-1090
Open Access | Times Cited: 14
Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, et al.
Diabetes Therapy (2018) Vol. 9, Iss. 4, pp. 1549-1567
Open Access | Times Cited: 13
Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio
Masayuki Kaneko, Mamoru Narukawa
Clinical Drug Investigation (2018) Vol. 39, Iss. 2, pp. 179-186
Closed Access | Times Cited: 12
Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
Theocharis Koufakis, Νικόλαος Παπάνας, George Dimitriadis, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 12, pp. 942-945
Open Access | Times Cited: 11
Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors
Mouhamed Nashawi, Omar Sheikh, Ayman Battisha, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 3, pp. 643-652
Closed Access | Times Cited: 11
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents
Zheng Li, Xue Xu, Liming Deng, et al.
Bioorganic & Medicinal Chemistry (2018) Vol. 26, Iss. 14, pp. 3947-3952
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top